表紙
市場調查報告書

Orexin第一型受體:開發平台分析

Orexin Receptor Type 1 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 359824
出版日期 內容資訊 英文 78 Pages
訂單完成後即時交付
價格
Back to Top
Orexin第一型受體:開發平台分析 Orexin Receptor Type 1 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 78 Pages
簡介

本報告提供以Orexin第一型受體為標的的藥物適應症,開發階段,作用機制,給藥途徑及各分子類型分析,藥物的藥理作用之相關記述,並彙整迄今的研究開發趨勢,最新的新聞和發表,藥物的主要開發企業概要,休止/中止的計劃等資訊。

簡介

  • 調查範圍

Orexin第一型受體概要

治療藥的開發

Orexin第一型受體:開發中的產品 - 各開發階段

Orexin第一型受體:開發中的產品 - 治療範圍別

Orexin第一型受體:開發中的產品 - 各適應症

Orexin第一型受體:開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

Orexin第一型受體:企業開發中的產品

Orexin第一型受體:治療藥的評估

  • 單劑療法/聯合治療產品別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

Orexin第一型受體的治療藥開發企業

  • C4X Discovery Holdings PLC
  • Eisai
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Merck & Co., Inc.

藥物簡介

Orexin第一型受體:暫停中的計劃

Orexin第一型受體:開發中止的產品

Orexin第一型受體:主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2032TDB

Summary

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) pipeline Target constitutes close to 14 molecules. The latest report Orexin Receptor Type 1 - Pipeline Review, H2 2019, outlays comprehensive information on the Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Orexin receptor type 1 (Ox1R or OX1) is a protein that is encoded by the HCRTR1 gene. The orexin 1 receptor (OX1) is a G-protein coupled receptor that is highly expressed in projections from the lateral hypothalamus and is involved in the regulation of feeding behavior. OX1 selectively binds the orexin-A neuropeptide. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2, 2, 7 and 1 respectively. Report covers products from therapy areas Central Nervous System and Respiratory which include indications Binge Eating Disorder, Nicotine Addiction, Insomnia, Addiction, Alcohol Addiction, Drug Addiction, Obstructive Sleep Apnea, Anxiety Disorders, Dementia Associated With Alzheimer's Disease, Major Depressive Disorder, Narcolepsy, Opioid Use Disorder, Panic Disorders, Parkinson's Disease, Pathological Gambling, Sleep Disorders and Smoking Cessation.

Furthermore, this report also reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • The report reviews Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Overview
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Companies Involved in Therapeutics Development
  • Chronos Therapeutics Ltd
  • Eisai Co Ltd
  • Eolas Therapeutics Inc
  • Idorsia Pharmaceutical Ltd
  • Indivior Plc
  • Inexia Ltd
  • Johnson & Johnson
  • OXonium Therapeutics
  • Sosei Heptares
  • Yangtze River Pharmaceutical Group
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Drug Profiles
  • ACT-539313 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CT-010018 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CTDP-002 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Antagonize Ox1 Receptor for Binge Eating Disorder - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EORA-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • INDV-2000 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JNJ-3215 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • lemborexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • nemorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • OPN-021 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Orexin-1 Receptor for Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Mollecules to Antagonize HCRTR1 for Addiction - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • suvorexant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • YZJ-1139 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Dormant Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Discontinued Products
  • Orexin Receptor Type 1 (Hypocretin Receptor Type 1 or HCRTR1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 10, 2019: Eisai presents new findings on Lemborexant as potential Sleep-Wake disorder therapy at 12th Clinical Trials on Alzheimer's Disease (CTAD) conference
  • Dec 09, 2019: Altasciences to conduct clinical trial for Opioid Use Disorder under NIH funding
  • Dec 02, 2019: Eisai to present latest data on lemborexant at 12th Clinical Trials on Alzheimer's Disease Conference
  • Nov 22, 2019: A sleeping pill that doesn't make you sway: a new targeted insomnia treatment
  • Oct 24, 2019: Trial to test insomnia drug for alcohol use disorder
  • Sep 27, 2019: Three new analyses of data expand understanding of the potential role for investigational agent Lemborexant in Insomnia and Irregular Sleep-Wake Rhythm Disorder
  • Sep 26, 2019: Announcement of National Institutes of Health (NIH) grant award through the NIH helping to end addiction long-term (HEAL) initiative
  • Sep 19, 2019: Eisai to present latest data on Lemborexant at World Sleep Congress
  • Jul 11, 2019: Latest data on Eisai's lemborexant to be presented at Alzheimer's Association International Conference (AAIC) 2019
  • Jun 13, 2019: Efficacy and safety data with Idorsias dual orexin receptor antagonist presented at SLEEP 2019 in San Antonio
  • Jun 11, 2019: Extensive analyses of phase 3 data for investigational Lemborexant assess efficacy and safety profile for the potential treatment of insomnia in adults
  • May 28, 2019: Eisai to present eight Lemborexant posters at SLEEP 2019 meeting, Including new pooled analyses from phase 3 studies and new phase 1 data
  • May 09, 2019: Merck's Belsomra achieves Phase III efficacy endpoints for insomnia
  • Apr 24, 2019: Eisai to present on lemborexant at the 2019 American Academy of Neurology Annual Meeting
  • Mar 11, 2019: Eisai and Imbrium Therapeutics announce U.S. FDA filing acceptance of New Drug Application for lemborexant for the treatment of insomnia
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Chronos Therapeutics Ltd, H2 2019
  • Pipeline by Eisai Co Ltd, H2 2019
  • Pipeline by Eolas Therapeutics Inc, H2 2019
  • Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
  • Pipeline by Indivior Plc, H2 2019
  • Pipeline by Inexia Ltd, H2 2019
  • Pipeline by Johnson & Johnson, H2 2019
  • Pipeline by OXonium Therapeutics, H2 2019
  • Pipeline by Sosei Heptares, H2 2019
  • Pipeline by Yangtze River Pharmaceutical Group, H2 2019
  • Dormant Projects, H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top